Payment overview · 2025
General Payments
$8,446.82
228 reported records · 45 companies
Healthcare provider profile · identity verified
Eduardo Miranda, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · LAREDO, TX · NPI 1285673012
Verified facts
What the public records show
CMS Open Payments records show Eduardo Miranda, M.D. received $8,446.82 in general payments during 2025 across 228 reported records.
OnMark, Inc. accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 88 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bosulif, Erleada, Ibrance, Inlyta, Jakafi, Kisqali, Lenvima, Lonsurf, Lynparza, Ojjaara, Orserdu, Pomalyst, Tagrisso, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Bosulif by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lynparza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Pomalyst by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lenvima as an associated drug or biological on 16833 records involving 7014 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lenvima by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ojjaara by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Imbruvica by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LENVIMA as an associated drug or biological on 66 records involving 58 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lenvima by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 10903 records involving 6595 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lynparza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KISQALI as an associated drug or biological on 31637 records involving 7959 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Kisqali by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOSULIF as an associated drug or biological on 3017 records involving 2109 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Bosulif by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INLYTA as an associated drug or biological on 2646 records involving 1964 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Inlyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xtandi by this doctor in 2024.
Stemline Therapeutics Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Orserdu as an associated drug or biological on 8512 records involving 4386 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Orserdu by this doctor in 2024.
TAIHO ONCOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LONSURF as an associated drug or biological on 4796 records involving 2963 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lonsurf by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| OnMark, Inc. | Unresolved — no canonical attribution shown | $2,991.80 | 35.4% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $523.38 | 6.2% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $366.82 | 4.3% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $343.72 | 4.1% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $315.55 | 3.7% | 13 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $260.11 | 3.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $252.69 | 3.0% | 13 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $226.44 | 2.7% | 10 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $212.02 | 2.5% | 5 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $203.02 | 2.4% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $183.73 | 2.2% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $179.03 | 2.1% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $174.83 | 2.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $160.98 | 1.9% | 7 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $147.97 | 1.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $143.15 | 1.7% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $135.43 | 1.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $118.25 | 1.4% | 5 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $115.36 | 1.4% | 5 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.59 | 1.3% | 6 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $106.77 | 1.3% | 5 | 2025 |
| SEAGEN INC. | Unresolved — no canonical attribution shown | $99.95 | 1.2% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $92.23 | 1.1% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $91.98 | 1.1% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $83.79 | 1.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $74.90 | 0.9% | 3 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $72.08 | 0.8% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $69.49 | 0.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.30 | 0.7% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $54.59 | 0.7% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.12 | 0.6% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $48.06 | 0.6% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $45.74 | 0.5% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $44.78 | 0.5% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $40.88 | 0.5% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $37.05 | 0.4% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.26 | 0.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.45 | 0.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.76 | 0.3% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.69 | 0.3% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.17 | 0.2% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.98 | 0.2% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.70 | 0.2% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $19.40 | 0.2% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.83 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,357.36 | 217 |
| Travel and Lodging | $1,533.65 | 2 |
| Education | $536.07 | 8 |
| Gift | $19.74 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $242.08 | 9 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $215.26 | 15 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $212.02 | 5 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $202.92 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $196.83 | 8 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $195.16 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $183.73 | 8 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological, Drug | Janssen Biotech, Inc., Legend Biotech USA Inc. | $173.00 | 3 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $171.51 | 8 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $169.71 | 13 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $149.49 | 7 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $147.97 | 2 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $118.25 | 5 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $113.59 | 6 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, Merck Sharp & Dohme LLC | $112.74 | 5 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $108.65 | 5 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $104.58 | 4 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $104.58 | 4 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $103.36 | 4 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $103.36 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $95.66 | 3 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $92.23 | 5 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $92.23 | 4 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $91.98 | 4 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $89.97 | 4 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $88.79 | 4 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $83.79 | 4 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $82.71 | 4 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $82.71 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $80.56 | 7 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $76.11 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $75.02 | 5 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $72.20 | 5 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $72.08 | 3 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $69.49 | 3 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $65.99 | 3 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $63.97 | 3 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $63.62 | 3 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $63.62 | 3 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $60.83 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $55.38 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $54.59 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $54.03 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $53.13 | 3 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $49.41 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $48.67 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $47.84 | 2 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $45.74 | 2 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $44.10 | 4 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $41.55 | 3 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $35.26 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $35.26 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| POMALYST Normalized: pomalyst |
Drug | Celgene Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeiGene USA, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| TIVDAK Normalized: tivdak |
Biological | PFIZER INC. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $10.94 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $10.94 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $7.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOSULIF bosulif |
2025 | Bosulif | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ERLEADA erleada |
2025 | Erleada | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INLYTA inlyta |
2025 | Inlyta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KISQALI kisqali |
2025 | Kisqali | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Lenvima lenvima |
2025 | Lenvima | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LONSURF lonsurf |
2025 | Lonsurf | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYNPARZA lynparza |
2025 | Lynparza | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Orserdu orserdu |
2025 | Orserdu | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| POMALYST pomalyst |
2025 | Pomalyst | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1228863907 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Lenvima open payments reported associated product |
CMS Open Payments — General Payments 16833 supporting records · 7014 recipient NPIs · example record 1244455619 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LENVIMA open payments reported associated product |
CMS Open Payments — General Payments 66 supporting records · 58 recipient NPIs · example record 1237995778 |
Lenvima · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 10903 supporting records · 6595 recipient NPIs · example record 1237992238 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | KISQALI open payments reported associated product |
CMS Open Payments — General Payments 31637 supporting records · 7959 recipient NPIs · example record 1200004789 |
Kisqali · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | BOSULIF open payments reported associated product |
CMS Open Payments — General Payments 3017 supporting records · 2109 recipient NPIs · example record 1228795613 |
Bosulif · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | INLYTA open payments reported associated product |
CMS Open Payments — General Payments 2646 supporting records · 1964 recipient NPIs · example record 1228795917 |
Inlyta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Stemline Therapeutics Inc. Exact reporting entity; no affiliate inference |
2025 | Orserdu open payments reported associated product |
CMS Open Payments — General Payments 8512 supporting records · 4386 recipient NPIs · example record 1244089377 |
Orserdu · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| TAIHO ONCOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | LONSURF open payments reported associated product |
CMS Open Payments — General Payments 4796 supporting records · 2963 recipient NPIs · example record 1211403676 |
Lonsurf · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 110 | 36 |
| Hydroxyurea | Hydroxyurea | 55 | 15 |
| Inlyta | Axitinib | 48 | suppressed |
| Xtandi | Enzalutamide | 47 | suppressed |
| Kisqali | Ribociclib Succinate | 46 | suppressed |
| Letrozole | Letrozole | 44 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 21 |
| Ondansetron Odt | Ondansetron | 36 | 32 |
| Xgeva | Denosumab | 35 | suppressed |
| Bicalutamide | Bicalutamide | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 12 |
| Megestrol Acetate | Megestrol Acetate | 26 | 19 |
| Tasigna | Nilotinib Hcl | 25 | suppressed |
| Erleada | Apalutamide | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Bosulif | Bosutinib | 20 | suppressed |
| Pomalyst | Pomalidomide | 20 | suppressed |
| Exemestane | Exemestane | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Imbruvica | Ibrutinib | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | 16 |
| Prednisone | Prednisone | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | 13 |
| Sunitinib Malate | Sunitinib Malate | 17 | suppressed |
| Lenvima | Lenvatinib Mesylate | 16 | suppressed |
| Losartan Potassium | Losartan Potassium | 16 | suppressed |
| Lynparza | Olaparib | 16 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Ibrance | Palbociclib | 15 | suppressed |
| Orserdu | Elacestrant Hcl | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Lonsurf | Trifluridine/Tipiracil Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 12 | suppressed |
| Tagrisso | Osimertinib Mesylate | 12 | suppressed |
| Everolimus | Everolimus | 11 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 11 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,446.82 · 228 records | OnMark, Inc. | ADCETRIS, AKEEGA, AYVAKIT, BALVERSA, BESREMI, BLENREP, BOSULIF, BRAFTOVI, BRUKINSA, CALQUENCE, CARVYKTI, DANZITEN, DARZALEX, ELREXFIO, ENHERTU, ERLEADA, Epkinly, FOTIVDA, Fabhalta, Gavreto, IBRANCE, ICLUSIG, IMFINZI, INLYTA, INQOVI, Itovebi, JAKAFI, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LONSURF, LORBRENA, LYNOZYFIC, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, NINLARO, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, POMALYST, POTELIGEO, PYRUKYND, Polivy, QINLOCK, REBLOZYL, ROMVIMZA, RYBREVANT, RYTELO, Rezlidhia, SARCLISA, SCEMBLIX, Stivarga, TAGRISSO, TALVEY, TALZENNA, TAVALISSE, TECVAYLI, TIVDAK, TUKYSA, Tecentriq Hybreza, Trodelvy, ULTOMIRIS, VENCLEXTA, Vitrakvi, Vonjo, Vyloy, WELIREG, XALKORI, XPOVIO, XTANDI, Xofigo, ZEJULA, ZEPZELCA, ZYNLONTA, ZYNYZ | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bosulif play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error